Treatment begins at low doses with gradual increases every 4 weeks to minimize side effects
In a meta-analysis of three trials, with a total of 1,119 participants, those with PAM variants were less responsive to the drugs and less successful in lowering their HbA1c, a measure of average blood sugar levels
This article explains the expected timeline, the factors that influence individual response, and the current regulatory status of retatrutide in the UK
Research has demonstrated that GLP-1 receptor activation produces several effects relevant to addiction: First, these medications reduce alcohol-induced dopamine release in the nucleus accumbens without affecting baseline dopaminergic function
Clinicians should monitor patients regularly and adjust expectations based on individual progress rather than population averages
In clinical trials, retatrutide has been administered as a subcutaneous injection meaning it is injected into the fatty tissue just beneath the skin once weekly